BCR-ABL is a gene produced by the fusion of the bcr gene and the c-abl proto-oncogene and is considered to be the main cause of chronic myelogenous leukemia (CML) production. Therefore, the development of selective Bcr-Abl kinase inhibitors is an attractive strategy for the treatment of CML.
AST 487
From $100
AT9283
From $90
Bosutinib
From $75
CZC-8004
From $165
Dasatinib
From $75
Dasatinib Hydrochloride
From $80
DCC-2036
From $90
DPH
From $100
Flumatinib mesylate
From $75
GNF-2
From $79
GNF-5
From $80
GNF-7, Ras Signaling Inhibitor
From $129
GZD824
From $90
Imatinib
From $80
Imatinib Mesylate
From $80
KW 2449
From $95
Nilotinib
From $75
ON 146040
From $130
PD173955
From $120
Ponatinib
From $132
SRI-37330 HCl
$100
Vodobatinib
From $105